169 related articles for article (PubMed ID: 23094081)
1. The carboxyl-terminus of human immunodeficiency virus type 2 circulating recombinant form 01_AB capsid protein affects sensitivity to human TRIM5α.
Miyamoto T; Nakayama EE; Yokoyama M; Ibe S; Takehara S; Kono K; Yokomaku Y; Pizzato M; Luban J; Sugiura W; Sato H; Shioda T
PLoS One; 2012; 7(10):e47757. PubMed ID: 23094081
[TBL] [Abstract][Full Text] [Related]
2. Novel mutant human immunodeficiency virus type 1 strains with high degree of resistance to cynomolgus macaque TRIMCyp generated by random mutagenesis.
Sultana T; Nakayama EE; Tobita S; Yokoyama M; Seki Y; Saito A; Nomaguchi M; Adachi A; Akari H; Sato H; Shioda T
J Gen Virol; 2016 Apr; 97(4):963-976. PubMed ID: 26795727
[TBL] [Abstract][Full Text] [Related]
3. A single amino acid of human immunodeficiency virus type 2 capsid protein affects conformation of two external loops and viral sensitivity to TRIM5α.
Miyamoto T; Yokoyama M; Kono K; Shioda T; Sato H; Nakayama EE
PLoS One; 2011; 6(7):e22779. PubMed ID: 21829511
[TBL] [Abstract][Full Text] [Related]
4. The Three-Fold Axis of the HIV-1 Capsid Lattice Is the Species-Specific Binding Interface for TRIM5α.
Morger D; Zosel F; Bühlmann M; Züger S; Mittelviefhaus M; Schuler B; Luban J; Grütter MG
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237846
[TBL] [Abstract][Full Text] [Related]
5. Multiple sites in the N-terminal half of simian immunodeficiency virus capsid protein contribute to evasion from rhesus monkey TRIM5α-mediated restriction.
Kono K; Song H; Yokoyama M; Sato H; Shioda T; Nakayama EE
Retrovirology; 2010 Sep; 7():72. PubMed ID: 20825647
[TBL] [Abstract][Full Text] [Related]
6. Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction.
Stremlau M; Perron M; Welikala S; Sodroski J
J Virol; 2005 Mar; 79(5):3139-45. PubMed ID: 15709033
[TBL] [Abstract][Full Text] [Related]
7. Naturally Occurring Mutations in HIV-1 CRF01_AE Capsid Affect Viral Sensitivity to Restriction Factors.
Nakayama EE; Saito A; Sultana T; Jin Z; Nohata K; Shibata M; Hosoi M; Motomura K; Shioda T; Sangkitporn S; Loket R; Saeng-Aroon S
AIDS Res Hum Retroviruses; 2018 Apr; 34(4):382-392. PubMed ID: 29325426
[TBL] [Abstract][Full Text] [Related]
8. A novel envelope mediated post entry restriction of murine leukaemia virus in human cells is Ref1/TRIM5α independent.
Oliveira NM; Trikha R; McKnight Á
Retrovirology; 2010 Oct; 7():81. PubMed ID: 20929586
[TBL] [Abstract][Full Text] [Related]
9. Functional replacement of the RING, B-box 2, and coiled-coil domains of tripartite motif 5alpha (TRIM5alpha) by heterologous TRIM domains.
Li X; Li Y; Stremlau M; Yuan W; Song B; Perron M; Sodroski J
J Virol; 2006 Jul; 80(13):6198-206. PubMed ID: 16775307
[TBL] [Abstract][Full Text] [Related]
10. Interaction of human immunodeficiency virus-1 and human immunodeficiency virus-2 capsid amino acid variants with human tripartite motif 5α protein SPRY domain and its association with pathogenesis.
Ramalingam VV; Subramanian S; Fletcher GJ; Rupali P; Varghese G; Pulimood S; Jeyaseelan L; Nandagopal B; Sridharan G; Kannangai R
Indian J Med Microbiol; 2019; 37(4):574-583. PubMed ID: 32436883
[TBL] [Abstract][Full Text] [Related]
11. Rhesus TRIM5α disrupts the HIV-1 capsid at the inter-hexamer interfaces.
Zhao G; Ke D; Vu T; Ahn J; Shah VB; Yang R; Aiken C; Charlton LM; Gronenborn AM; Zhang P
PLoS Pathog; 2011 Mar; 7(3):e1002009. PubMed ID: 21455494
[TBL] [Abstract][Full Text] [Related]
12. HIV-2 CRF01_AB: first circulating recombinant form of HIV-2.
Ibe S; Yokomaku Y; Shiino T; Tanaka R; Hattori J; Fujisaki S; Iwatani Y; Mamiya N; Utsumi M; Kato S; Hamaguchi M; Sugiura W
J Acquir Immune Defic Syndr; 2010 Jul; 54(3):241-7. PubMed ID: 20502347
[TBL] [Abstract][Full Text] [Related]
13. Gag cytotoxic T lymphocyte escape mutations can increase sensitivity of HIV-1 to human TRIM5alpha, linking intrinsic and acquired immunity.
Battivelli E; Migraine J; Lecossier D; Yeni P; Clavel F; Hance AJ
J Virol; 2011 Nov; 85(22):11846-54. PubMed ID: 21917976
[TBL] [Abstract][Full Text] [Related]
14. HIV-2 capsids distinguish high and low virus load patients in a West African community cohort.
Onyango CO; Leligdowicz A; Yokoyama M; Sato H; Song H; Nakayama EE; Shioda T; de Silva T; Townend J; Jaye A; Whittle H; Rowland-Jones S; Cotten M
Vaccine; 2010 May; 28 Suppl 2():B60-7. PubMed ID: 20510746
[TBL] [Abstract][Full Text] [Related]
15. Rhesus monkey TRIM5α SPRY domain recognizes multiple epitopes that span several capsid monomers on the surface of the HIV-1 mature viral core.
Biris N; Tomashevski A; Bhattacharya A; Diaz-Griffero F; Ivanov DN
J Mol Biol; 2013 Dec; 425(24):5032-44. PubMed ID: 23886867
[TBL] [Abstract][Full Text] [Related]
16. Caging the beast: TRIM5α binding to the HIV-1 core.
Diaz-Griffero F
Viruses; 2011 May; 3(5):423-8. PubMed ID: 21994740
[TBL] [Abstract][Full Text] [Related]
17. An invariant surface patch on the TRIM5alpha PRYSPRY domain is required for retroviral restriction but dispensable for capsid binding.
Sebastian S; Grütter C; Strambio de Castillia C; Pertel T; Olivari S; Grütter MG; Luban J
J Virol; 2009 Apr; 83(7):3365-73. PubMed ID: 19153241
[TBL] [Abstract][Full Text] [Related]
18. High level of susceptibility to human TRIM5α conferred by HIV-2 capsid sequences.
Takeuchi JS; Perche B; Migraine J; Mercier-Delarue S; Ponscarme D; Simon F; Clavel F; Labrosse B
Retrovirology; 2013 May; 10():50. PubMed ID: 23647667
[TBL] [Abstract][Full Text] [Related]
19. Role of TRIM5α RING domain E3 ubiquitin ligase activity in capsid disassembly, reverse transcription blockade, and restriction of simian immunodeficiency virus.
Kim J; Tipper C; Sodroski J
J Virol; 2011 Aug; 85(16):8116-32. PubMed ID: 21680520
[TBL] [Abstract][Full Text] [Related]
20. Assisted evolution enables HIV-1 to overcome a high TRIM5α-imposed genetic barrier to rhesus macaque tropism.
Soll SJ; Wilson SJ; Kutluay SB; Hatziioannou T; Bieniasz PD
PLoS Pathog; 2013; 9(9):e1003667. PubMed ID: 24086139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
